Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Didanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ALB | P02768 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.48 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Didanosine SCHEMBL3364 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL12150307 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7910803 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL8709115 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7910809 | 0.99 | ALDH1A1 (0.60) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7907423 | 0.97 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL7907418 | 0.97 | ALDH1A1 (0.59) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL9223571 | 0.94 | ALDH1A1 (0.56) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL8025110 | 0.94 | ALDH1A1 (0.58) | ALDH1A1LMNAALBMAPK1ABL1 | |
| Didanosine SCHEMBL9594496 | 0.93 | ADA (0.58) | ALDH1A1LMNAALBMAPK1ADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9713622-B2 | Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV) | UNIVERSITÉ VERSAILLES SAINT-QUENTIN-EN-YVELINES (FR) | 2017-07-25 | — | — | US | disclosed |
| EP-2501386-B1 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Assistance Publique Hôpitaux De Paris (FR) | 2016-01-27 | — | — | EP | disclosed |
| US-20150374727-A1 | NOVEL SCHEDULES FOR ADMINISTERING COMBINATION THERAPIES USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20150305983-A1 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | UNIVERSITÉ VERSAILLES SAINT-QUENTIN-EN-YVELINES (FR) | 2015-10-29 | — | — | US | disclosed |
| US-9101633-B2 | Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (HIV) | THE UNIVERSITY OF VERSAILLES SAINT-QUENTIN-EN-YVELINES (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20120270828-A1 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | THE UNIVERSITY OF VERSAILLES SAINT-QUENTIN-EN-YVELINES (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2501386-A1 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Assistance Publique Hôpitaux De Paris (FR) | 2012-09-26 | — | — | EP | disclosed |
| EP-2332544-A1 | New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV) | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011061303-A1 | QUADRUPLE THERAPY USEFUL FOR TREATING PERSONS AFFLICTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2011-05-26 | — | — | WO | disclosed |
| EP-0707481-B1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | UNIV YALE (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5830881-A | L-2'3',dideoxy nucleoside analogs as anti-hepatitus B (HBV) agents | YALE UNIVERSITY (US) | 1998-11-03 | — | — | US | disclosed |
| US-5631239-A | VIRICIDES FOR HEPATITIS | YALE UNIVERSITY (US) | 1997-05-20 | — | — | US | disclosed |
| US-5627160-A | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents | YALE UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5561120-A | LOW TOXICITY TO HOST CELLS | YALE UNIVERSITY (US) | 1996-10-01 | — | — | US | disclosed |
| EP-0707481-A4 | — | — | 1996-05-29 | — | — | EP | disclosed |
| EP-0707481-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994027616-A1 | L-2',3'-DIDEOXY NUCLEOSIDE ANALOGS AS ANTI-HEPATITIS B (HBV) AND ANTI-HIV AGENTS | YALE UNIVERSITY (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5011774-A | Dideoxyinosine by enzymatic deamination of dideoxyadenosine | BRISTOL-MYERS SQUIBB CO. (US) | 1991-04-30 | — | — | US | disclosed |
| EP-0285884-A2 | Process to produce 2', 3'-Dideoxynucleosides | Bristol-Myers Squibb Company (US) | 1988-10-12 | — | — | EP | disclosed |